keyword
MENU ▼
Read by QxMD icon Read
search

Androgen deprivation therapy

keyword
https://www.readbyqxmd.com/read/27910803/the-prognostic-and-predictive-value-of-tmprss2-erg-gene-fusion-and-erg-protein-expression-in-prostate-cancer-biopsies
#1
Kasper Drimer Berg
BACKGROUND: The clinical course of prostate carcinoma (PCa) is very heterogeneous. Consequently, a personalised approach for risk stratification and treatment planning is important. Recently, it has become evident that PCa, also at the genomic level, is heterogeneous. An early and common alteration is the gene fusion between the transmembrane protease serine 2 (TMPRSS2) gene and the v-ets avian erythroblastosis virus E26 oncogene homolog (ERG) gene resulting in expression of the oncoprotein ERG...
December 2016: Danish Medical Journal
https://www.readbyqxmd.com/read/27905327/potential-therapeutic-effect-of-epigenetic-therapy-on-treatment-induced-neuroendocrine-prostate-cancer
#2
Xiang Xu, Yu-Hua Huang, Yan-Jing Li, Alexa Cohen, Zhen Li, Jill Squires, Wei Zhang, Xu-Feng Chen, Min Zhang, Jiao-Ti Huang
Although adenocarcinomas of the prostate are relatively indolent, some patients with advanced adenocarcinomas show recurrence of treatment-induced neuroendocrine prostate cancer, which is highly aggressive and lethal. Detailed biological features of treatment-induced neuroendocrine prostate cancer have not been characterized owing to limited biopsies/resections and the lack of a cellular model. In this study, we used a unique cellular model (LNCaP/NE1.8) to investigate the potential role of cancer stem cells in treatment-induced neuroendocrine prostate cancer with acquired resistance to hormonal therapy and chemotherapy...
November 29, 2016: Asian Journal of Andrology
https://www.readbyqxmd.com/read/27898031/inherited-variants-in-wnt-pathway-genes-influence-outcomes-of-prostate-cancer-patients-receiving-androgen-deprivation-therapy
#3
Jiun-Hung Geng, Victor C Lin, Chia-Cheng Yu, Chao-Yuan Huang, Hsin-Ling Yin, Ta-Yuan Chang, Te-Ling Lu, Shu-Pin Huang, Bo-Ying Bao
Aberrant Wnt signaling has been associated with many types of cancer. However, the association of inherited Wnt pathway variants with clinical outcomes in prostate cancer patients receiving androgen deprivation therapy (ADT) has not been determined. Here, we comprehensively studied the contribution of common single nucleotide polymorphisms (SNPs) in Wnt pathway genes to the clinical outcomes of 465 advanced prostate cancer patients treated with ADT. Two SNPs, adenomatous polyposis coli (APC) rs2707765 and rs497844, were significantly (p ≤ 0...
November 26, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27893042/androgen-deprivation-therapy-and-dose-escalated-radiotherapy-for-intermediate-and-high-risk-prostate-cancer-sign-of-changing-times
#4
Deepansh Dalela, Patrick Karabon, Firas Abdollah
No abstract text is available yet for this article.
November 23, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27893029/androgen-deprivation-therapy-and-dose-escalated-radiotherapy-for-intermediate-and-high-risk-prostate-cancer-reply
#5
Aaron D Falchook, Ramsankar Basak, Ronald C Chen
No abstract text is available yet for this article.
November 23, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27892725/investigational-serine-threonine-kinase-inhibitors-against-prostate-cancer-metastases
#6
Claudio Festuccia
INTRODUCTION: Androgen deprivation therapy (ADT) is used as first therapeutic approach in prostate cancer (PCa) although castration resistant disease (CRPC) develops with high frequency. CRPC is the consequence of lack of apoptotic responses to ADT. Alternative targeting of the androgen axis with abiraterone and enzalutamide, as well as taxane-based chemotherapy were used in CRPC. Serine/threonine protein kinases (STKs) regulate different molecular pathways of normal and neoplastic cells and participate to development of CRPC as well as to the progression towards a bone metastatic disease (mCRPC)...
November 28, 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27888148/a-pilot-study-of-a-multimodal-treatment-paradigm-to-accelerate-drug-evaluations-in-early-stage-metastatic-prostate-cancer
#7
Matthew J O'Shaughnessy, Sean M McBride, Hebert Alberto Vargas, Karim A Touijer, Michael J Morris, Daniel C Danila, Vincent P Laudone, Bernard H Bochner, Joel Sheinfeld, Erica S Dayan, Lawrence P Bellomo, Daniel D Sjoberg, Glenn Heller, Michael J Zelefsky, James A Eastham, Peter T Scardino, Howard I Scher
OBJECTIVE: To evaluate a multimodal strategy aimed at treating all sites of disease that provides a rapid readout of success or failure in men presenting with noncastrate metastatic prostate cancers that are incurable with single modality therapy. PATIENTS AND METHODS: Twenty selected men with oligometastatic M1a (extrapelvic nodal disease) or M1b (bone disease) at diagnosis were treated using a multimodal approach that included androgen deprivation, radical prostatectomy plus pelvic lymphadenectomy (retroperitoneal lymphadenectomy in the presence of clinically positive retroperitoneal nodes), and stereotactic body radiotherapy to osseous disease and/or the primary site...
November 22, 2016: Urology
https://www.readbyqxmd.com/read/27888135/antihypertensive-effects-of-androgens-in-conscious-spontaneously-hypertensive-rats
#8
Mercedes Perusquía, Nieves Herrera, Mercedes Ferrer, John N Stallone
Androgens are vasoactive steroids that induce acute vasodilation in a number of isolated vascular beds from different species, but the effects of these hormones on systemic blood pressure (BP) have been studied little. Although it has been reported that androgens exert systemic hypotensive effects through peripheral vasodilation in normotensive rats, there have not been any reports of systemic hypotensive effects of androgens in animals with hypertension. This study was designed to evaluate the acute effects of testosterone (TES) and its 5-reduced metabolites on systemic BP in hypertensive rats and to test the hypothesis that hypotestosteronemia may be involved in the pathogenesis of hypertension...
November 23, 2016: Journal of Steroid Biochemistry and Molecular Biology
https://www.readbyqxmd.com/read/27887941/functional-outcomes-and-quality-of-life-after-radical-prostatectomy-only-versus-a-combination-of-prostatectomy-with-radiation-and-hormonal-therapy
#9
Meike Adam, Pierre Tennstedt, Dominik Lanwehr, Derya Tilki, Thomas Steuber, Burkhard Beyer, Imke Thederan, Hans Heinzer, Alexander Haese, Georg Salomon, Lars Budäus, Uwe Michl, Dirk Pehrke, Pär Stattin, Jürgen Bernard, Bernd Klaus, Raisa S Pompe, Cordula Petersen, Hartwig Huland, Markus Graefen, Rudolf Schwarz, Wolfgang Huber, Stacy Loeb, Thorsten Schlomm
BACKGROUND: While the optimal use and timing of secondary therapy after radical prostatectomy (RP) remain controversial, there are limited data on patient-reported outcomes following multimodal therapy. OBJECTIVE: To assess the impact of additional radiation therapy (RT) and/or androgen deprivation therapy (ADT) on urinary continence, potency, and quality of life (QoL) after RP. DESIGN, SETTING, AND PARTICIPANTS: Among 13150 men who underwent RP from 1992 to 2013, 905 received RP + RT, 407 RP + ADT and 688 RP + RT + ADT...
November 22, 2016: European Urology
https://www.readbyqxmd.com/read/27878044/a-comparative-study-of-radical-prostatectomy-and-permanent-seed-brachytherapy-for-low-and-intermediate-risk-prostate-cancer
#10
Daniel Taussky, Véronique Ouellet, Guila Delouya, Fred Saad
INTRODUCTION: We sought to compare the outcomes between radical prostatectomy (RP) and permanent seed prostate brachytherapy (PB) in patients with low- and low-intermediate-risk prostate cancer from a single tertiary care centre. METHODS: Patients were selected from our institute's internal database based on preoperative selection criteria from the National Comprehensive Cancer Network (NCCN) guidelines (2015) for low- and intermediate-risk patients. No patient had received any neo-adjuvant androgen-deprivation therapy...
August 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/27870566/androgen-deprivation-therapy-and-the-risk-of-dementia-in-patients-with-prostate-cancer
#11
Farzin Khosrow-Khavar, Soham Rej, Hui Yin, Armen Aprikian, Laurent Azoulay
Purpose Recent observational studies have associated the use of androgen deprivation therapy (ADT) with an increased risk of dementia and Alzheimer's disease, but these studies had limitations. The objective of this study was to determine whether the use of ADT is associated with an increased risk of dementia, including Alzheimer's disease, in patients with prostate cancer. Patients and Methods Using the United Kingdom's Clinical Practice Research Datalink, we assembled a cohort of 30,903 men newly diagnosed with nonmetastatic prostate cancer between April 1, 1988 and April 30, 2015, and observed them until April 30, 2016...
November 21, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27863287/bone-health-in-the-elderly-cancer-patient-a-siog-position-paper
#12
REVIEW
J J Body, E Terpos, B Tombal, P Hadji, A Arif, A Young, M Aapro, R Coleman
More than a third of cancers are diagnosed in people over the age of 75. Androgen deprivation for prostate cancer and aromatase inhibitors in breast cancer accelerate age-related bone loss and increase fracture rates. BMD should be checked by dual energy X-ray absorptiometry at baseline and, dependent on risk, every 12-24months. Sufficient calcium, vitamin D and exercise are part of primary fracture prevention. Resistance exercise in particular may improve functional activity and bone density. In men at increased fracture risk and women with postmenopausal early breast cancer, antiresorptive treatment is warranted to reduce fracture rate and to increase overall survival in breast cancer...
December 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/27863019/78gy-with-fiducial-marker-image-guided-radiotherapy-in-prostate-cancer-single-center-analysis-of-301-patients
#13
Ee Siang Choong, George Hruby, Jean Yang, Carol Kwong, Nitya Patanjali
AIM: In prostate cancer, fiducial marker image-guided radiotherapy (FMIGRT) allows correction of setup errors and interfraction physiological motion resulting in improved accuracy of target and sparing of at risk organs. We aim to report outcomes and toxicities observed in patients treated with dose escalation to 78Gy with FMIGRT in our center. METHODS AND MATERIALS: Retrospective review of consecutive patients with histologically confirmed T1-4N0M0 localized prostate cancer treated with dose escalation to 78Gy with FMIGRT in our center...
November 10, 2016: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/27859018/the-role-of-adjuvant-radiotherapy-in-pathologically-lymph-node-positive-prostate-cancer
#14
Naresh Jegadeesh, Yuan Liu, Chao Zhang, Jim Zhong, Richard J Cassidy, Theresa Gillespie, Omer Kucuk, Peter Rossi, Viraj A Master, Mehrdad Alemozaffar, Ashesh B Jani
BACKGROUND: Postoperative management of prostate cancer with lymph node involvement (LNI) is controversial. Retrospective evidence supports the selective use of radiotherapy (RT) after extended pelvic lymph node dissection. It is unclear whether this is generalizable to practice in the United States, where extended dissection is uncommon. The authors identified patients with LNI who potentially could derive a survival benefit with adjuvant RT plus androgen-deprivation therapy (ADT). METHODS: Patients with N1M0 prostate adenocarcinoma who underwent radical prostatectomy (RP) and subsequently received ADT from 2003 through 2011 were identified from the National Cancer Database...
November 8, 2016: Cancer
https://www.readbyqxmd.com/read/27856956/the-efflux-transporter-abcg2-maintains-prostate-stem-cells
#15
Neha G Sabnis, Austin Miller, Mark A Titus, Wendy J Huss
: Prostate Stem Cells (PSCs) are characterized by their intrinsic resistance to Androgen Deprivation Therapy (ADT), possibly due to the lack of Androgen Receptor (AR) expression. PSCs resistance to ADT and PSC expansion in Castration Recurrent Prostate Cancer (CRPC) has sparked great interest in using differentiation therapy as an adjuvant to ADT. Understanding the mechanisms, by which PSCs maintain their undifferentiated phenotype, thus has important implications in differentiation therapy...
November 17, 2016: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/27846936/-ccafu-french-national-guidelines-2016-2018-on-prostate-cancer
#16
F Rozet, C Hennequin, J-B Beauval, P Beuzeboc, L Cormier, G Fromont, P Mongiat-Artus, A Ouzzane, G Ploussard, D Azria, I Brenot-Rossi, G Cancel-Tassin, O Cussenot, T Lebret, X Rebillard, M Soulié, R Renard-Penna, A Méjean
OBJECTIVES: The purpose of the guidelines national committee CCAFU was to propose updated french guidelines for localized and metastatic prostate cancer (PCa). METHODS: A Medline search was achieved between 2013 and 2016, as regards diagnosis, options of treatment and follow-up of PCa, to evaluate different references with levels of evidence. RESULTS: Epidemiology, classification, staging systems, diagnostic evaluation are reported. Disease management options are detailed...
November 2016: Progrès en Urologie
https://www.readbyqxmd.com/read/27843596/international-survey-of-androgen-deprivation-therapy-adt-for-non-metastatic-prostate-cancer-in-19-countries
#17
Alexander Liede, David C Hallett, Kirsty Hope, Alex Graham, Jorge Arellano, Vahakn B Shahinian
BACKGROUND: Continuous androgen deprivation therapy (CADT) is commonly used for patients with non-metastatic prostate cancer as primary therapy for high-risk disease, adjuvant therapy together with radiation or for recurrence after initial local therapy. Intermittent ADT (IADT), a recently developed alternative strategy for providing ADT, is thought to potentially reduce adverse effects, but little is known about practice patterns relating to it. We aimed to describe factors related to physicians' ADT use and modality for patients with non-metastatic prostate cancer...
2016: ESMO Open
https://www.readbyqxmd.com/read/27843206/role-of-systemic-chemotherapy-in-metastatic-hormone-sensitive-prostate-cancer
#18
REVIEW
Niraj Shenoy, Manish Kohli
INTRODUCTION: Patients with metastatic hormone sensitive prostate cancer (mHSPC) have traditionally been treated with androgen deprivation therapy (ADT). Recently, there has been a demonstration of a survival benefit with the addition of docetaxel to ADT from three large randomized controlled trials. This review summarizes these trials, draws comparisons between the trials, and attempts to provide critical evidence-based recommendation on the role of docetaxel in mHSPC. METHODS: Of the two published (GETUG-AFU, Chemo-Hormonal therapy vs...
October 2016: Indian Journal of Urology: IJU: Journal of the Urological Society of India
https://www.readbyqxmd.com/read/27837416/a-simple-prognostic-model-involving-prostate-specific-antigen-alkaline-phosphatase-and-albumin-for-predicting-the-time-required-to-progress-to-castration-resistant-prostate-cancer-in-patients-who-received-androgen-deprivation-therapy
#19
Wei Lv, Hongxiang Shang, Xinqi Pei, Yule Chen, Hongjun Xie, Dalin He, Xinyang Wang, Lei Li
PURPOSE: To distinguish potential biomarkers and build a useful model to predict the time required to progress to castration-resistant prostate cancer (CRPC) in patients with prostate cancer who have been treated with androgen deprivation therapy (ADT). METHODS: We considered 168 patients who received ADT as the initial therapy. Complete clinical data including age, tumor stage, Gleason score, prostate-specific antigen (PSA), complete blood count and liver function tests were analyzed...
November 11, 2016: International Urology and Nephrology
https://www.readbyqxmd.com/read/27836866/sequencing-of-sipuleucel-t-and-androgen-deprivation-therapy-in-men-with-hormone-sensitive-biochemically-recurrent-prostate-cancer-a-phase-ii-randomized-trial
#20
Emmanuel S Antonarakis, Adam S Kibel, Evan Y Yu, Lawrence I Karsh, Aymen Elfiky, Neal D Shore, Nicholas J Vogelzang, John M Corman, Frederick E Millard, Johnathan C Maher, Nancy Chang, Todd DeVries, Nadeem A Sheikh, Charles G Drake
BACKGROUND: STAND, a randomized, phase II, open-label trial (NCT01431391) assessed sequencing of sipuleucel-T (an autologous cellular immunotherapy) with androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC) patients at high risk for metastasis. METHODS: Men with BRPC following prostatectomy and/or radiotherapy, a prostate-specific antigen (PSA) doubling time (PSADT)less than or equal to 12 months, and no metastasis were enrolled. Patients were randomized (34/arm) to sipuleucel-T followed by ADT (started 2 weeks after sipuleucel-T completion), or ADT followed by sipuleucel-T (started 12 weeks after ADT initiation); ADT continued for 12 months in both arms...
November 10, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
keyword
keyword
58120
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"